John F. Gerecitano, MD, PhD

Clinical Director of Lymphoma Outpatient Services
John F. Gerecitano, MD, PhD

I am a medical oncologist/hematologist who is a member of a close-knit team that provides compassionate, multidisciplinary care to patients with lymphoma. I have clinical expertise in both Hodgkin and non-Hodgkin lymphoma, and my research interests focus on finding new treatments for patients with these diseases. To accomplish this goal, I serve as the principal investigator on several clinical trials that evaluate promising new treatments from laboratories around the world. I have helped develop agents now approved to treat lymphoma, including bortezomib and ibrutinib. Many of my trials explore innovative ways to combine existing drugs with newer treatments in order to find novel ways to maximize responses while minimizing side effects in patients with lymphoma. I am also a member of the Developmental Therapeutics Group, a team of medical oncologists dedicated to providing access to the newest phase I agents for patients with all types of cancer throughout Memorial Sloan Kettering.

Appointments for New Patients
Clinical Expertise

Hodgkin and Non-Hodgkin Lymphomas; Clinical Trials and New Drug Development in Lymphoma and Solid Tumors

Languages Spoken

MD, PhD, New York University School of Medicine


Hospital of the University of Pennsylvania


Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology

Publications by John F. Gerecitano
Visit PubMed for full listing of John F. Gerecitano journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.